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M. Lipman5,6
Despite recent declines in reported tuberculosis (TB) rates in India, the disease remains a major 
public health challenge.1,2 With an estimated 2.8 mil-
lion incident cases in 2015 (217 per 100 000 popula-
tion),1 India is considered a high-burden country for 
TB by the World Health Organization (WHO). The re-
ported treatment success rate was 88% for new and re-
lapse cases registered in 20133 and 74% for those regis-
tered in 2014;1 the apparent decline is most likely 
influenced by revisions to the estimates of the overall 
TB burden for the period 2000–2015.1
In India, most health care is delivered through the 
private sector, where >70% of health care contacts4,5 
and an estimated 60% of TB patients6 are seen. Out-of-
pocket expenditure can be high5 and the poorest indi-
viduals often have limited health care access.7 So-
cio-economic position (SEP) is associated with an 
increased risk for TB,8 delays in seeking treatment9 
and loss to follow-up (LTFU).10 Other risk factors for 
TB disease include male sex, previous anti-tuberculosis 
treatment, alcohol consumption, increasing age, low 
body mass index (BMI) and tobacco use;8 several of 
these factors are also associated with LTFU and death 
during treatment.10,11
In this article, we identify risk factors for unfavour-
able treatment outcomes in a vulnerable population 
receiving treatment through the non-governmental 
organisation (NGO) Operation ASHA (New Delhi, In-
dia), which aims to enhance case identification and 
treatment delivery for patients who might not seek 
care through the Revised National Tuberculosis Con-
trol Programme (RNTCP).
STUDY POPULATION AND METHODS
Data collection
Operation ASHA (New Delhi, India, www/opasha.org/) 
works with national programmes to provide free health 
services, including TB diagnostics and treatment, in In-
dia’s urban slums and poor rural areas, where health 
care access is typically limited.12,13 Their approach in-
cludes community engagement, patient empowerment 
and biometric technology. During the study period, the 
organisation operated in seven Indian states (Figure 1), 
running TB centres in collaboration with local health 
care practitioners and the RNTCP.
We used data for patients diagnosed based on 
symptoms and sputum smears through Operation 
ASHA between April 2012 and September 2014. Fol-
lowing diagnosis, all TB patients initiate directly ob-
served treatment (DOT), delivered by trained commu-
nity members. Patients were included if they had 
pulmonary TB with an initial sputum smear result or 
extra-pulmonary TB, and were not multidrug-resistant 
(MDR, defined as TB that is resistant to both isoniazid 
[H] and rifampicin [R]) at presentation.
At each DOT visit, the provider records drug admin-
istration using biometric software (including finger-
print identification of patient and provider) on a tablet 
computer.14 Demographic and clinical information is 
entered at enrolment, including age, sex, initial spu-
tum smear status, site of disease (pulmonary or ex-
tra-pulmonary; patients with both pulmonary and ex-
tra-pulmonary TB are classified as having pulmonary 
disease), and patient category (Category I, no previous 
anti-tuberculosis treatment or treatment for <1 month, 
or Category II, previous treatment for 1 month).
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Setting: Urban slums and poor rural areas in India, 
2012–2014.
Objective: To describe the characteristics of tuberculosis 
(TB) patients enrolled in treatment through Operation 
ASHA, a non-governmental organisation serving disad-
vantaged populations in India, and to identify risk factors 
for unfavourable treatment outcomes.
Design: This was a retrospective cohort study. Patient 
characteristics were assessed for their relationship with 
treatment outcomes using mixed effects logistic regres-
sion, adjusting for clustering by treatment centre and In-
dian state. Outcomes were considered favourable (cured/
treatment completed) or unfavourable (treatment failure, 
loss to follow-up, death, switch to multidrug-resistant TB 
treatment, transfer out).
Results: Of 8415 patients, 7148 (84.9%) had a favour-
able outcome. On multivariable analysis, unfavourable 
outcomes were more common among men (OR 1.31, 
95%CI 1.15–1.51), older patients (OR 1.12, 95%CI 1.04–
1.21) and previously treated patients (OR 2.05, 95%CI 
1.79–2.36). Compared to pulmonary smear-negative pa-
tients, those with extra-pulmonary disease were less likely 
to have unfavourable outcomes (OR 0.72, 95%CI 0.60–
0.87), while smear-positive pulmonary patients were 
more likely to have unfavourable outcomes (OR 1.38, 
95%CI 1.15–1.66 for low [scanty/1+] and OR 1.71, 
95%CI 1.44–2.04 for high [2+/3+] positive smears).
Conclusion: The treatment success rate within Opera-
tion ASHA is comparable to that reported nationally for 
India. Men, older patients, retreatment cases and 
smear-positive pulmonary TB patients may need addi-
tional interventions to ensure a favourable outcome.
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Treatment regimens
Following India’s national guidelines, treatment con-
sists of an intensive phase including supervision of all 
doses, followed by a continuation phase with every 
third dose supervised.15 Treatment comprises three 
doses/week throughout and lasts 6–9 months, depend-
ing upon the patient category, and, for pulmonary TB 
patients, sputum smear status after the intensive phase 
(Figure 2). The intensive phase comprises 2 months of 
HR, pyrazinamide (Z) and ethambutol (E), plus in-
jected streptomycin (S) for Category II patients, for 
whom the intensive phase also includes an additional 
month of HRZE only. At the end of the intensive 
phase, patients provide a sputum sample; if positive, 
treatment is continued for one further month. After 
this time, or at the time of the sputum sample if nega-
tive, patients move to the continuation phase: 4 
months of HR for Category I patients or 5 months of 
HRE for Category II patients. Additional sputum sam-
ples are taken 2 months into the continuation phase 
and at treatment completion; patients with repeated 
positive results are evaluated and treated for MDR-TB if 
appropriate. Any missed doses are added to the end of 
treatment: all patients who complete treatment will 
have taken the full prescribed number of doses.
Treatment outcomes
Treatment outcomes are defined in Table 1. In our pri-
mary analysis, outcomes were dichotomised into fa-
vourable (cured or treatment completed) and unfa-
vourable/neutral (treatment failure, LTFU, death, 
switch to MDR-TB treatment or transferred out—here-
after described as unfavourable), consistent with WHO 
measures of treatment success.3
Statistical analysis
Data were initially summarised descriptively. The fol-
lowing explanatory variables were then assessed for 
associations with the binary treatment outcome using 
univariate mixed effects logistic regression to estimate 
odds ratios (ORs) and 95% confidence intervals (CIs), 
accounting for clustering by treatment centre and 
state: age group (15, 16–24, 25–44 and 45 years), 
sex, treatment category, urban/rural location of treat-
ment centre and disease type. The latter combined site 
of disease and initial sputum smear status, and was 
categorised as pulmonary smear-negative, pulmonary 
low smear-positive (initial smear result scanty or 1+), 
pulmonary high smear-positive (2+ or 3+) or ex-
tra-pulmonary. Urban/rural location was classified fol-
lowing definitions used by the Census of India.16 Age 
group was treated as a linear rather than categorical 
variable after preliminary analysis found this pro-
duced a better-fitting model. A priori, we considered 
all of these factors as likely to be associated with treat-
ment outcomes, so all were included in a multivari-
able model. P values were derived using likelihood ra-
tio tests.
We conducted three sensitivity analyses. First, pa-
tients who were transferred out (final outcomes un-
known) were excluded. Second, because repeat epi-
sodes for the same patient cannot be identified in the 
data set, Category II patients were excluded. Third, we 
restricted analysis to extra-pulmonary and smear-nega-
tive pulmonary patients to investigate risk factors for 
not completing treatment (the operational outcome 
definitions preclude patients with either extra-pulmo-
nary or smear-negative pulmonary TB from being clas-
sified as cured).
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FIGURE 1 Geographical distribution of tuberculosis patients treated 
through Operation ASHA across seven Indian states.
FIGURE 2 Treatment regimens used in Operation ASHA as recom-
mended by the Indian national guidelines. H = isoniazid; R = rifampi-
cin; Z = pyrazinamide; E = ethambutol; S = streptomycin; TB = 
tuberculosis.
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Analyses were conducted in Stata v. 14 (StataCorp, College Sta-
tion, TX, USA); maps were drawn using the user-written spmap 
command17 and shapefiles downloaded from the Global Adminis-
trative Areas database.18
Ethical approval
Ethical approval was not sought, as data were collected during 
routine care and anonymised before analysis. Operation ASHA 
has permission from the RNTCP (New Delhi, India) to use anony-
mised data for research and public health purposes without in-
formed consent.
RESULTS
Between April 2012 and September 2014, 8415 patients with pul-
monary disease and a sputum smear result at the beginning of 
treatment or with extra-pulmonary disease were enrolled in an-
ti-tuberculosis treatment under Operation ASHA (Table 2). Pa-
tients were treated at 135 centres in seven states (range 1–453 pa-
tients per centre) (Figure 1).
The majority of the patients (58.3%) were male; the highest 
percentage (39.7%) were aged 25–44 years (Table 2). Almost all 
(95.9%) attended urban treatment centres. At enrolment, 35.0% 
had extra-pulmonary TB, 25.5% had smear-negative pulmonary 
disease, 19.7% had a low positive smear result and 19.8% had a 
high positive result. Overall, 20.9% of patients had previously re-
ceived anti-tuberculosis treatment, i.e., were Category II.
There were 7148 (84.9%) patients who had a favourable out-
come (2588 [36.2%]) cured, 4560 [63.8%] treatment completed). 
Of 1267 patients with an unfavourable outcome, 82 (6.5%) expe-
rienced treatment failure, 381 (30.1%) were lost to follow-up, 281 
(22.2%) died, 360 (28.4%) transferred out and 163 (12.9%) 
switched to MDR-TB treatment.
On univariate analysis, unfavourable outcomes were more 
common among males, in older age groups and in Category II vs. 
Category I patients (Table 3). Compared to pulmonary smear-neg-
ative patients, low and high smear-positive patients were increas-
ingly likely to have an unfavourable outcome, while extra-pulmo-
nary cases appeared less likely to have an unfavourable outcome. 
There was no evidence that outcomes differed between urban and 
rural settings.
On multivariable analysis, these associations remained, but 
were somewhat attenuated (Table 3). Males were more likely than 
females to have unfavourable outcomes (OR 1.31, 95%CI 1.15–
1.51, P < 0.001). Age remained associated with increasing odds of 
an unfavourable outcome (OR 1.12, 95%CI 1.04–1.21, P = 0.002), 
TABLE 1 Definitions of treatment outcomes
Outcome Definition
Cured The patient has taken all prescribed 
treatment doses and has converted from 
smear-positive to smear-negative
Treatment completed The patient has taken all doses and is 
smear-negative at the end of treatment 
without a previous positive smear
Treatment failure The patient is smear-positive after 5 
months of treatment and has not been 
detected as having MDR-TB
Loss to follow-up The patient has missed 2 months of 
consecutive doses (sometimes referred 
to as default)
Transfer out The patient has been transferred to 
another TB centre
Death The patient has died from TB or any other 
cause
Switch to MDR-TB treatment The patient has developed MDR-TB during 
treatment and has been placed on 
appropriate treatment
MDR-TB = multidrug-resistant TB; TB = tuberculosis.
TABLE 2 Demographic and clinical characteristics of TB patients enrolled in treatment through Operation ASHA and having initial smear 
results or extra-pulmonary TB, April 2012–September 2014
Patients
Favourable outcome
(n = 7148)
n (column %)
Unfavourable outcome
(n = 1267)
n (column %)
Total
(N = 8415)
n (column %)
Sex
 Female 3096 (43.3) 412 (32.5) 3508 (41.7)
 Male 4052 (56.7) 855 (67.5) 4907 (58.3)
Age group, years
 15 984 (13.8) 80 (6.3) 1064 (12.6)
 16–24 2028 (28.4) 338 (26.7) 2366 (28.1)
 25–44 2792 (39.1) 547 (43.2) 3339 (39.7)
 45 1344 (18.8) 302 (23.8) 1646 (19.6)
Setting
 Urban 6853 (95.9) 1216 (96.0) 8069 (95.9)
 Rural 295 (4.1) 51 (4.0) 346 (4.1)
Type of disease
 Pulmonary, smear-negative 1832 (25.6) 311 (24.6) 2143 (25.5)
 Pulmonary, low smear-positive 1364 (19.1) 290 (22.9) 1654 (19.7)
 Pulmonary, high smear-positive 1283 (18.0) 386 (30.5) 1669 (19.8)
 Extra-pulmonary 2669 (37.3) 280 (22.1) 2949 (35.0)
Previous TB history
 Category I 5818 (81.4) 838 (66.1) 6656 (79.1)
 Category II 1330 (18.6) 429 (33.9) 1759 (20.9)
TB = tuberculosis.
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as did increasing degree of sputum smear positivity (OR 1.38, 
95%CI 1.15–1.66 and OR 1.71, 95%CI 1.44–2.04 for low and high 
positive pulmonary TB patients vs. smear-negative). Extra-pulmo-
nary disease was associated with lower odds (OR 0.72, 95%CI 
0.60–0.87). Category II patients had approximately twice the odds 
of having an unfavourable outcome as Category I patients (OR 
2.05, 95%CI 1.79–2.36, P < 0.001).
Sensitivity analysis, excluding the 360 patients who were 
transferred out or the 1759 Category II patients, produced similar 
results (Table 4). Results based on the 5092 patients with pulmo-
nary smear-negative (n = 2143) or extra-pulmonary (n = 2949) dis-
ease were again similar (Table 4), although the OR for treatment 
category was reduced (OR 1.50, 95%CI 1.20–1.86, P < 0.001).
DISCUSSION
In this cohort from a disadvantaged population of TB patients in 
India, risk factors for unfavourable treatment outcomes were in-
creasing age, male sex, history of TB treatment and having pul-
monary, and particularly smear-positive, disease. Overall, Opera-
TABLE 3 Unadjusted and adjusted OR for the association between explanatory variables and unfavourable treatment outcomes for all 
patients. All estimates are adjusted for clustering by treatment centre and state
Unadjusted OR
(95%CI) P value
aOR*
(95% CI) P value
Sex
 Female Reference Reference
 Male 1.56 (1.37–1.78) <0.001 1.31 (1.15–1.51) <0.001
Age group
 Per category increase 1.28 (1.20–1.37) <0.001 1.12 (1.04–1.21) 0.002
Setting
 Urban Reference Reference
 Rural 1.09 (0.72–1.65) 0.70 0.85 (0.55–1.33) 0.48
Type of disease
 Pulmonary, smear-negative Reference Reference
 Pulmonary, low smear-positive 1.42 (1.19–1.71) 1.38 (1.15–1.66)
 Pulmonary, high smear-positive 1.88 (1.58–2.24) 1.71 (1.44–2.04)
 Extra-pulmonary 0.65 (0.54–0.78) <0.001 0.72 (0.60–0.87) <0.001
Previous TB history
 Category I Reference Reference
 Category II 2.39 (2.09–2.74) <0.001 2.05 (1.79–2.36) <0.001
* Adjusted for all other variables in table.
OR = odds ratio; aOR = adjusted odds ratio; CI = confidence interval; TB = tuberculosis.
TABLE 4 Adjusted ORs and 95%CIs for the association between explanatory variables and unfavourable treatment outcomes obtained in 
sensitivity analyses which excluded 1) patients with a recorded outcome of transfer out, 2) patients with a recorded history of previous 
anti-tuberculosis treatment (Category II patients), or 3) patients with smear-positive pulmonary disease. All estimates are adjusted for clustering 
by treatment centre and state
Variables
Excluding transfer out patients 
(n = 8055)
Excluding
Category II patients
(n = 6656)
Excluding smear-positive pulmonary 
TB patients
(n = 5092)
aOR* (95%CI) P value aOR† (95%CI) P value aOR* (95%CI) P value
Sex
 Female Reference Reference Reference
 Male 1.34 (1.14–1.57) <0.001 1.29 (1.10–1.52) 0.002 1.36 (1.12–1.64) 0.001
Age group
 Per category increase 1.14 (1.04–1.24) 0.004 1.19 (1.10–1.30) <0.001 1.23 (1.12–1.36) <0.001
Setting
 Urban Reference Reference Reference
 Rural 1.13 (0.72–1.76) 0.60 0.98 (0.61–1.58) 0.94 0.59 (0.28–1.24) 0.15
Type of disease
 Pulmonary, smear-negative Reference Reference Reference
 Pulmonary, low smear-positive 1.69 (1.36–2.08) 1.17 (0.94–1.46) NA
 Pulmonary, high smear-positive 2.09 (1.70–2.56) 1.41 (1.14–1.75) NA
 Extra-pulmonary 0.65 (0.52–0.82) <0.001 0.69 (0.56–0.85) <0.001 0.76 (0.63–0.93) 0.006
Previous TB history
 Category I Reference NA NA Reference
 Category II 2.45 (2.10–2.87) <0.001 NA NA 1.50 (1.20–1.86) <0.001
* Adjusted for all other variables in table.
† Adjusted for all other variables in table except previous TB history.
OR = odds ratio; CI = confidence interval; TB = tuberculosis; aOR = adjusted OR; NA = not applicable.
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tion ASHA successfully treated 84.9% of the patients in our 
analysis. This is comparable to national data reported from India 
(treatment success rate of 88% among new and relapse cases regis-
tered in 2013,19 74% for 20141), and approaches the 90% target 
set for 2025 in the WHO’s End TB strategy,20 despite the fact that 
Operation ASHA works with highly vulnerable patients. Previous 
studies in India have reported similar treatment success rates, e.g., 
76.7% in patients positive for the human immunodeficiency vi-
rus (HIV) and 93.5% in HIV-negative patients,21 93% with com-
munity DOT and 75% with institutional DOT,22 and 74.3% in 
HIV-positive and 79.9% in HIV-negative patients.23 While we are 
not aware of any estimates for drug-susceptible TB specifically for 
highly disadvantaged populations, 48% of 23 HIV-positive 
MDR-TB patients in a Mumbai slum had favourable outcomes.24
The age and sex distribution of TB patients treated by Opera-
tion ASHA differed from that of TB patients in India nationally: in 
the national data, 9% of patients are aged <15 years and 35% are 
female,1 compared to respectively 12.6% and 41.7% in our data 
set. A lower percentage of Operation ASHA patients have pulmo-
nary disease (65.0%) compared to national data (82%).1 These dif-
ferences may reflect Operation ASHA’s aim to reach patients who 
otherwise may never receive care.
The relationships we observed between treatment outcome 
and age, sex and previous treatment have been previously re-
ported, in India and elsewhere.10,11,25–27 In a rural area of South 
India in 1999–2000, the odds of LTFU were higher among men 
than women (adjusted OR [aOR] 3.4, 95%CI 1.5–8.2), in patients 
aged 45 years compared to younger patients (aOR 1.6, 95%CI 
1.0–2.6), and in previously treated patients compared to those 
with no previous treatment (aOR 2.8, 95%CI 1.6–4.9).11 In con-
trast with our results, that study found no association between 
site of disease and LTFU, although only univariate results were 
presented and the point estimate suggested higher rates of LTFU 
among extra-pulmonary patients (OR 2.8, 95%CI 0.99–11.1).11 
Our comparison of urban and rural settings is limited by the small 
number of patients in rural areas.
Although the data were very complete for the included covari-
ates, we lacked information on several relevant exposures. Impor-
tantly, HIV status is not well reported in the data set. In Indian 
national data, 4% of TB patients with known HIV status are 
HIV-positive;1 an HIV prevalence of 1.2% was reported for men 
living in slums in Chennai in 2001–2002.28 We also lacked data 
on smoking. Among patients attending a designated microscopy 
centre in South India, 41.5% of presumptive TB patients and 80% 
of smear-positive pulmonary TB patients reported tobacco use in 
the previous month.29 Smoking may therefore be common in the 
study population, increasing the risk of poor outcomes.11,30–32 Al-
though we had no data on SEP, the populations with whom Oper-
ation ASHA works are extremely disadvantaged even in compari-
son to other TB patients in India. The great majority of Operation 
ASHA’s patients (96%) live in urban slums. Slum residents have 
previously been identified as a high-risk group for TB in India 
(aOR 1.6, 95%CI 1.00–2.45 for culture-positive pulmonary TB),8 
although disease is not confined to this group; the prevalence was 
0.4% in slum dwellers and 0.2% in other residents of urban 
Chennai.8
Previous studies of pulmonary TB outcomes according to 
smear status have produced varying results.33 This has been sug-
gested to be related to HIV prevalence, especially advanced HIV 
disease, which is associated with low bacillary burden in the spu-
tum.34 While extra-pulmonary TB has been associated with longer 
treatment delays,35 HIV infection36 and worse outcomes than pul-
monary TB,26 higher treatment success among extra-pulmonary 
patients has also been reported.37 This depends partly on the site 
of extra-pulmonary disease; for example, meningeal and dissemi-
nated TB have higher mortality rates than lymphatic TB.38 As pa-
tients with solely extra-pulmonary disease will not have a positive 
sputum smear at enrolment, they cannot be classified as ‘cured’, 
which requires smear conversion. We therefore conducted a sensi-
tivity analysis restricted to extra-pulmonary and initially 
smear-negative pulmonary cases; the association between site of 
disease and outcome persisted. This could result from residual 
confounding by measured or unmeasured factors, such as treat-
ment adherence, or because patients with both pulmonary and 
extra-pulmonary disease were classified as pulmonary cases. A 
univariate analysis of data from the RNTCP on TB-HIV patients, 
however, reported lower treatment success amongst pulmonary 
cases (OR 0.58, 95%CI 0.40–0.83),37 consistent with our results.
Our analysis does not include patients with MDR-TB. Risk fac-
tors for poor outcomes of MDR-TB, particularly in disadvantaged 
populations, should be further investigated, as rates of treatment 
failure are higher in MDR-TB than in drug-susceptible TB.11,25
Current WHO treatment guidelines recommend daily dosing 
throughout treatment in both the intensive and continuation 
phases.39 If this is not feasible, recommended alternatives are 
daily dosing during the intensive phase and three times per week 
during the continuation phase, all directly observed; or, for pa-
tients not living with HIV and not in a setting with high HIV 
prevalence, directly observed doses three times weekly through-
out the intensive and continuation phases.39 The treatment regi-
men used by Operation ASHA, and recommended by the RNTCP, 
maintains the WHO-recommended dosing frequency, but with 
direct observation of only every third dose during the continua-
tion phase. Further clinical follow-up data on relapses are needed 
to better assess the adequacy of this regimen in this population.
The percentage of patients who are successfully treated de-
pends partly on mortality rates from causes other than TB, which 
may be high in this population and might reduce the treatment 
success rate. Without cause-specific mortality data, this is difficult 
to address. Our approach is consistent with the WHO’s method of 
assessing treatment success. Deaths from other causes undoubt-
edly contribute to the increased risk of unfavourable outcome in 
older age groups, but other factors, including delayed presenta-
tion35 and difficulties in diagnosis and treatment40 in the elderly, 
may also be relevant.
CONCLUSIONS
Operation ASHA appears to be achieving treatment success rates 
comparable to those reported through national surveillance1,3 
and epidemiological studies conducted in India.21–23 However, we 
have not formally evaluated the programme, including its bio-
metric technology and electronic data recording components, 
and our analysis does not contain a comparison group, which 
would be necessary to assess the effectiveness and cost-effective-
ness of the service. Reaching vulnerable populations such as those 
described in this study will be essential if the goals of the End TB 
strategy20 are to be achieved.
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Contexte  :  Bidonvilles urbains et zones rurales pauvres, Inde, 
2012–2014.
Objectif  :  Décrire les caractéristiques des patients atteints de 
tuberculose (TB) enrôlés dans un traitement à travers l’Opération 
ASHA, une organisation non-gouvernementale au service des 
populations désavantagées en Inde, et identifier les facteurs de risque 
de résultat défavorable du traitement.
Schéma  :  Etude rétrospective de cohorte. Les caractéristiques des 
patients ont été évaluées en fonction de leur relation avec les résultats 
du traitement grâce à une régression logistique à effets mixtes ajustée 
sur le regroupement par centre de traitement et par l’état d’Inde. Le 
résultat a été considéré comme favorable (guéri/traitement achevé) 
ou défavorable (échec du traitement, perte de vue, décès, évolution 
vers un traitement de TB multirésistante, transfert).
Résultats  :  De 8415 patients, 7148 (84,9%) ont eu un résultat 
favorable. En analyse multi-variable, les résultats défavorables ont été 
plus fréquents parmi les hommes (OR 1,31 ; IC 95% 1,15–1,51), les 
patients plus âgés (OR 1,12 ; IC95% 1,04–1,21) et les patients déjà 
traités (OR 2,05 ; IC95% 1,79–2,36). Comparés aux patients atteints 
de TB pulmonaire à frottis négatif, les patients atteints de TB extra-
pulmonaire ont été moins susceptibles d’avoir un résultat défavorable 
(OR 0,72 ; IC95% 0,60–0,87), tandis que les patients atteints de TB 
pulmonaire à frottis positif ont été plus susceptibles d’avoir un 
résultat défavorable (OR 1,38 ; IC95% 1,15–1,66 pour les frottis 
positifs faibles [rares/1+] et OR 1,71 ; IC95% 1,44–2,04 pour les 
frottis élevés [2+/3+]).
Conclusion  :  Le taux de succès du traitement dans le cadre de 
l’Opération ASHA est comparable à celui rapporté au niveau national 
en Inde. Les hommes, les patients plus âgés, les cas en retraitement 
et les patients atteints de TB pulmonaire à frottis positif pourraient 
avoir besoin d’interventions supplémentaires afin d’assurer un résultat 
favorable.
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Marco de referencia: Barriadas urbanas y zonas rurales pobres en la 
India del 2012 al 2014.
Objetivo: Describir las características de los pacientes con 
tuberculosis (TB) inscritos en tratamiento en el marco de la Operación 
ASHA, que es una organización no gubernamental que atiende a las 
poblaciones desfavorecidas en la India, y determinar los factores de 
riesgo de obtener desenlaces terapéuticos desfavorables.
Método: Un estudio retrospectivo de cohortes. Las características de 
los pacientes se evaluaron con respecto a los desenlaces terapéuticos, 
mediante un análisis de regresión logística de efectos mixtos y ajuste 
con relación a los conglomerados, según el centro de tratamiento y el 
estado de la India. Los desenlaces se consideraron favorables 
(curación o tratamiento completo) o desfavorables (fracaso 
terapéutico, pérdida durante el seguimiento, muerte, cambio de 
tratamiento por TB multirresistente o transferencia a otro centro).
Resultados: De los 8415 pacientes, en 7148 el desenlace fue 
favorable (84,9%). El análisis multivariante reveló que los desenlaces 
desfavorables eran más frecuentes en los hombres (OR 1,31; IC95% 
1,15–1,51), los ancianos (OR 1,12; IC95% 1,04–1,21) y en los 
pacientes con antecedente de tratamiento antituberculoso (OR 2,05; 
IC95% 1,79–2,36). Tomando como referencia a los pacientes con 
baciloscopia negativa, los desenlaces desfavorables fueron menos 
probables en los pacientes con TB extrapulmonar (OR 0,72; IC95% 
0,60–0,87) y más probables en los pacientes con TB pulmonar y 
baciloscopia positiva (OR 1,38; IC95% 1,15–1,66 para las 
baciloscopias bajas, de escasos bacilos a 1+ y OR 1,71; IC95% 1,44–
2,04 para las baciloscopia altas, de 2+ o 3+).
Conclusión: La tasa de éxito del tratamiento antituberculoso en 
el marco de la Operación ASHA es equivalente a la notificada a 
escala nacional en la India. Los pacientes de sexo masculino, los 
ancianos, los casos en retratamiento y los que presentan una TB 
pulmonar con baciloscopia positiva pueden necesitar 
intervenciones complementarias a fin de fomentar los desenlaces 
favorables.
